Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued
The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.
Diagnosis & Disease Information
Treatment Without ADT Delays Initiation of Systemic Therapy in Prostate Cancer
Metastasis-directed therapy can delay initiation of systemic therapy in patients with solitary oligorecurrent metastatic lesion
MPR Weekly Dose Podcast #127
Novavax vaccine booster update; over-the-counter hearing aids; Priority Review for a castration-resistant prostate cancer combination treatment; first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection.
Olaparib + Abiraterone Gets Priority Review for Castration-Resistant Prostate Cancer
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer
The approval was based on data from the phase 3 ARASENS trial.
Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Prevalence of CRC Screening Remains Low in Those Aged 50 to 54
Increase in screening differed by age, with 19.4 percent increase for those aged 50 to 54 and 31.6 percent increase for those aged 70 to 75
Enzalutamide Active in Low-, Intermediate-Risk Prostate Cancer
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
Higher Dairy Intake May Up Risk for Prostate Cancer
However, association does not hold for nondairy calcium intake
